©2022 Stanford Medicine
Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study
Not Recruiting
Trial ID: NCT04381091
Purpose
Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy
who completed the LEROS Study
Official Title
Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study
Stanford Investigator(s)
Y. Joyce Liao, MD, PhD
Professor of Ophthalmology and of Neurology
Eligibility
Inclusion Criteria:
- Patients who completed the LEROS study, who attended the end of study visit in LEROS
and who in the opinion of investigator could benefit from continuation of idebenone
treatment.
- Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from
patient or parent/legal guardian (if applicable) prior to dispensing idebenone to the
patient).
Exclusion Criteria:
- Patients who, in the opinion of the LEROS investigator, had unacceptable tolerability
of idebenone treatment in LEROS trial.
- Patients who prematurely discontinued the LEROS study.
Intervention(s):
drug: Idebenone 150 MG Oral Tablet
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305